Effects of Creatine and Resistance Exercise Training in People With HIV Infection
This study was designed determine whether use of creatine monohydrate, a dietary supplement, can increase skeletal muscle mass and strength and improve the response to progressive resistance exercise training in people with HIV infection.
Procedure: Use of creatine monohydrate (a dietary supplement)
Behavioral: Progressive resistance exercise training
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Supportive Care
|Official Title:||Ergogenic Effects of Creatine Supplementation in HIV Infection|
- Muscle strength [ Time Frame: 14 weeks ]
- Muscle size [ Time Frame: 14 weeks ]
- Muscle energetics [ Time Frame: 14 weeks ]
- Body composition [ Time Frame: 14 weeks ]
- Biochemistries [ Time Frame: 14 weeks ]
- Safety [ Time Frame: Throughout the study ]
|Study Start Date:||August 2001|
|Study Completion Date:||October 2003|
This is a randomized, placebo-controlled study to evaluate the effect of creatine monohydrate, a dietary supplement, on skeletal muscle size and function (i.e., strength, energy metabolism, work capacity, fatigue); whole-body exercise performance; and body composition. This study is also designed to determine whether creatine supplementation augments the functional benefit derived from progressive resistance exercise. The safety of creatine supplementation in people with HIV infection will also be evaluated. Forty HIV-positive subjects will be randomly assigned, on a 1:1 basis, to receive creatine monohydrate or placebo for a period of 14 days, followed by a 12-week program of supervised progressive resistance exercise training during which administration of creatine monohydrate or placebo will continue.
Measurements of muscle strength, size, composition, energetics and fatigue, as well as body weight and composition and serum biochemistries, will be made at baseline, after two weeks of treatment with creatine or placebo (before PRT), and again after 12 weeks of PRT (study week 14). Safety will be monitored throughout the study.
|United States, California|
|San Francisco General Hospital|
|San Francisco, California, United States, 94110|
|Principal Investigator:||Morris Schambelan, MD||University of California, San Francisco; San Francisco General Hospital|
|Study Director:||Kathleen Mulligan, PhD||University of California, San Francisco; San Francisco General Hospital|